Trader consensus favoring no new coronavirus pandemic in 2026 reflects WHO’s July 2026 moderate global risk assessment for SARS-CoV-2, which continues circulating at endemic levels with variants such as XFG and BA.3.2 under monitoring. Genomic surveillance shows these Omicron descendants exhibit immune escape but limited replacement potential due to reduced fitness traits, while cumulative population immunity from prior waves and updated monovalent vaccines targeting dominant lineages keeps severe outcomes low. Official data indicate seasonal respiratory patterns rather than exponential growth meeting pandemic thresholds. A realistic challenge could arise from an undetected zoonotic spillover or compensatory mutations restoring high transmissibility and virulence in a novel strain, though current surveillance and historical precedent make rapid escalation unlikely before year-end.